pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 29 | Non-oncology: 19 Oncology: 10 |
Under Consideration for Negotiation | 26 | Non-oncology: 15 Oncology: 11 |
Completed Negotiations | 678 | With Letter of Intent: 581 Without agreement: 97 |
Negotiations That Were Not Pursued | 101 |
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Omvoh | Eli Lilly Canada Inc. | Ulcerative Colitis | |
Lynparza | AstraZeneca Canada Inc. | Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). | |
Koselugo | Alexion Pharma GMBH | For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas | |
Onivyde | Shire Pharma Canada ULC | Metastatic Pancreatic Cancer | |
Pemazyre | Incyte Biosciences Canada Corporation | For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, | |
Vyalev | AbbVie Corporation | For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease. | |
TheraSphere Y-90 Glass Micropheres | Boston Scientific Corporation | Hepatocellular carcinoma | |
SIR-Spheres Y-90 resin microspheres | Sirtex Medical | Hepatocellular carcinoma |